Davis AE, Brogan AJ, Goodwin B, Nocea G, Lozano V. Short-term cost and efficiency analysis of raltegravir versus atazanavir/ritonavir or darunavir/ritonavir for treatment-naive adults with HIV-1 infection in Spain. HIV Clin Trials. 2017 Nov;18(5-6):214-22. doi: 10.1080/15284336.2017.1402144
Kurosky SK, Davis KL, Galindo CM. Effect of combination vaccines on hepatitis B vaccine compliance in children in the United States. Pediatr Infect Dis J. 2017 Jul;36(7):e189-96. doi: 10.1097/INF.0000000000001548
Abeysinghe S, Margulis AV, Mauskopf J, Ainsworth C. Risk factors for RSV hospitalization in healthy preterm infants: a meta-analysis. Letter to the editor. Pediatr Infect Dis J. 2017 Jul;36(7):696. doi: 10.1097/INF.0000000000001559
Mauskopf J, Margulis AV, Samuel M, Lohr KN. Respiratory syncytial virus hospitalizations in healthy preterm infants: systematic review. Pediatr Infect Dis J. 2016 Jul;35(7):e229-38. doi: 10.1097/INF.0000000000001163
Brogan AJ, Mrus J, Hill A, Sawyer AW, Smets E. Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States. HIV Clin Trials. 2010 May;11(3):133-44.